ARTICLE | Clinical News

BGB-3111: Additional Ph I data

December 30, 2016 10:05 PM UTC

Data from 46 evaluable patients with chronic lymphocytic lymphoma (CLL) or small lymphocytic leukemia (SLL) in an open-label, dose-escalation, international Phase I trial showed that BGB-3111 led to an ORR of 96%, including 31 partial responses and 13 partial responses with lymphocytosis, plus 1 case of stable disease at a median follow-up of 8.6 months. No cases of disease progression or Richter's transformation have occurred. Three serious adverse events -- grade 2 cardiac failure, grade 2 pleural effusion and grade 3 purpura -- were determined to be possibly related to BGB-3111...

BCIQ Company Profiles

BeiGene Ltd.

BCIQ Target Profiles

Bruton's tyrosine kinase (Btk)